GLP1R and Hyperglycemia: Mendelian randomisation studies support a causal role of genetically driven hyperglycaemia in atherosclerotic CVD (ASCVD) [41–43] and show that glucose-lowering variants of the GLP-1 receptor (GLP-1R) gene, GLP1R, confer protection against heart disease [44].